These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 29193849)

  • 1. Apparent transverse relaxation (R2∗) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma.
    Belliveau JG; Bauman GS; Macdonald D; Macdonald M; Klassen LM; Menon RS
    J Med Imaging Radiat Oncol; 2018 Apr; 62(2):224-231. PubMed ID: 29193849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
    Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
    Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
    Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
    J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of a multiple spin- and gradient-echo (SAGE) EPI acquisition with SENSE acceleration: applications for perfusion imaging in and outside the brain.
    Skinner JT; Robison RK; Elder CP; Newton AT; Damon BM; Quarles CC
    Magn Reson Imaging; 2014 Dec; 32(10):1171-80. PubMed ID: 25179133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
    Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
    Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas.
    Ma B; Blakeley JO; Hong X; Zhang H; Jiang S; Blair L; Zhang Y; Heo HY; Zhang M; van Zijl PC; Zhou J
    J Magn Reson Imaging; 2016 Aug; 44(2):456-62. PubMed ID: 26788865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    Moon HH; Kim HS; Park JE; Kim YH; Kim JH
    BMC Cancer; 2021 Jun; 21(1):654. PubMed ID: 34074252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible, irreversible and effective transverse relaxation rates in normal aging brain at 3T.
    Sedlacik J; Boelmans K; Löbel U; Holst B; Siemonsen S; Fiehler J
    Neuroimage; 2014 Jan; 84():1032-41. PubMed ID: 24004692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma.
    Ceschin R; Kurland BF; Abberbock SR; Ellingson BM; Okada H; Jakacki RI; Pollack IF; Panigrahy A
    AJNR Am J Neuroradiol; 2015 Nov; 36(11):2170-6. PubMed ID: 26338910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
    Melguizo-Gavilanes I; Bruner JM; Guha-Thakurta N; Hess KR; Puduvalli VK
    J Neurooncol; 2015 May; 123(1):141-50. PubMed ID: 25894594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
    Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.
    Anwar M; Molinaro AM; Morin O; Chang SM; Haas-Kogan DA; Nelson SJ; Lupo JM
    Radiat Res; 2017 Sep; 188(3):303-313. PubMed ID: 28723274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
    van West SE; de Bruin HG; van de Langerijt B; Swaak-Kragten AT; van den Bent MJ; Taal W
    Neuro Oncol; 2017 May; 19(5):719-725. PubMed ID: 28453748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis.
    Abbasi AW; Westerlaan HE; Holtman GA; Aden KM; van Laar PJ; van der Hoorn A
    Clin Neuroradiol; 2018 Sep; 28(3):401-411. PubMed ID: 28466127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
    Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
    J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of Synthetic MRI for Direct Measurement of Magnetic Resonance Relaxation Time and Tumor Volume at Multiple Time Points after Contrast Administration: Preliminary Results in Patients with Brain Metastasis.
    Kang KM; Choi SH; Hwang M; Yoo RE; Yun TJ; Kim JH; Sohn CH
    Korean J Radiol; 2018; 19(4):783-791. PubMed ID: 29962885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADC texture--an imaging biomarker for high-grade glioma?
    Brynolfsson P; Nilsson D; Henriksson R; Hauksson J; Karlsson M; Garpebring A; Birgander R; Trygg J; Nyholm T; Asklund T
    Med Phys; 2014 Oct; 41(10):101903. PubMed ID: 25281955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
    Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
    J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.